https://catedra-mielomamultiple.com/evolving-m-protein-pattern-in-patients-with-smoldering-multiple-myeloma-impact-on-early-progression/https://catedra-mielomamultiple.com/la-ub-suma-esforcos-amb-amgen-per-millorar-la-formacio-en-mieloma-multiple/https://catedra-mielomamultiple.com/nectin-2-expression-on-malignant-plasma-cells-is-associated-with-better-response-to-tigit-blockade-in-multiple-myeloma/https://catedra-mielomamultiple.com/defining-an-optimal-dual-targeted-car-t-cell-therapy-approach-simultaneously-targeting-bcma-and-gprc5d-to-prevent-bcma-escape-driven-relapse-in-multiple-myeloma/https://catedra-mielomamultiple.com/primary-plasma-cell-leukemia-consensus-definition-by-the-international-myeloma-working-group-according-to-peripheral-blood-plasma-cell-percentage/https://catedra-mielomamultiple.com/t-cells-isolated-from-g-csf-treated-multiple-myeloma-patients-are-suitable-for-the-generation-of-bcma-directed-car-t-cells/https://catedra-mielomamultiple.com/prognostic-impact-of-myd88-and-cxcr4-mutations-assessed-by-droplet-digital-polymerase-chain-reaction-in-igm-monoclonal-gammopathy-of-undetermined-significance-and-smouldering-waldenstrom-macroglobulin/https://catedra-mielomamultiple.com/4a-reunio-cientifica-anual-gemmac/https://catedra-mielomamultiple.com/estada-rotacions-formativa-nacional/https://catedra-mielomamultiple.com/jornades-informatives-sobre-el-mieloma-multiple-2023-cemmp/https://catedra-mielomamultiple.com/jornada-informativa-sobre-mieloma-multiple-de-barcelona-2023-dr-carlos-fernandez-de-larrea/https://catedra-mielomamultiple.com/estada-formativa-internacional-beques-estrangeres/https://catedra-mielomamultiple.com/professor-a-associat-ada-universitat-de-barcelona/https://catedra-mielomamultiple.com/invitacio-ponents-sessions-cientifiques-hematologia/https://catedra-mielomamultiple.com/estrategies-noves-denginyeria-avancada-per-optimitzar-la-funcio-i-la-persistencia-de-les-cellules-car-t-al-mieloma-multiple/https://catedra-mielomamultiple.com/xarxes-de-recerca-cooperativa-orientades-a-resultats-en-salutacio-2021/https://catedra-mielomamultiple.com/strategies-to-overcome-antigen-escape-relapses-and-improve-car-t-cell-persistence-in-multiple-myeloma-2/https://catedra-mielomamultiple.com/assaig-clinic-fase-ii-sobre-lus-dun-cart-humanitzat-dirigit-contra-bcma/https://catedra-mielomamultiple.com/analysis-of-the-chromatin-accesibility-landscape-and-regulatory-networks-of-igm-monoclonal-gammopathies-towards-a-better-understanding-of-progression-mechanisms-2/https://catedra-mielomamultiple.com/immunotherapy-for-multiple-myeloma-2/https://catedra-mielomamultiple.com/optimitzacio-de-la-immunoterapia-amb-cellules-t-car-a-traves-de-la-inhibicio-dimmune-checkpoints-per-assolir-una-resposta-prologada-en-pacients-amb-mieloma-multiple/https://catedra-mielomamultiple.com/bcma-and-slamf7-chimeric-antigen-receptors-t-cells-immunotherapy-in-multiple-myeloma-2/https://catedra-mielomamultiple.com/tercera-jornada-informativa-sobre-el-mieloma-multiple-2/https://catedra-mielomamultiple.com/curs-aspectes-teoricopractics-damiloidosi-i-mieloma-multiple/https://catedra-mielomamultiple.com/preceptorship-a-mieloma-multiple/https://catedra-mielomamultiple.com/clinical-implications-of-genomic-profile-in-waldenstrom-macroglobulinemia/https://catedra-mielomamultiple.com/fractionated-initial-infusion-and-booster-dose-of-ari0002h-a-humanised-bcma-directed-car-t-cell-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma-cartbcma-hcb-01-a-single-arm-multicent/https://catedra-mielomamultiple.com/report-of-consensus-panel-3-from-the-11th-international-workshop-on-waldenstroms-macroglobulinemia-recommendations-for-molecular-diagnosis-in-waldenstroms-macroglobulinemia/https://catedra-mielomamultiple.com/report-of-consensus-panel-6-from-the-11-th-international-workshop-on-waldenstroms-macroglobulinemia-on-management-of-waldenstroms-macroglobulinemia-related-amyloidosis/https://catedra-mielomamultiple.com/cilta-cel-or-standard-care-in-lenalidomide-refractory-multiple-myeloma/https://catedra-mielomamultiple.com/characterization-of-the-endotheliopathy-innate-immune-activation-and-hemostatic-imbalance-underlying-car-t-cell-toxicities-laboratory-tools-for-an-early-and-differential-diagnosis/https://catedra-mielomamultiple.com/car-density-influences-antitumoral-efficacy-of-bcma-car-t-cells-and-correlates-with-clinical-outcome/https://catedra-mielomamultiple.com/paraskeletal-and-extramedullary-plasmacytomas-in-multiple-myeloma-at-diagnosis-and-at-first-relapse-50-years-of-experience-from-an-academic-institution/https://catedra-mielomamultiple.com/long-term-responders-after-autologous-stem-cell-transplantation-in-multiple-myeloma/https://catedra-mielomamultiple.com/diagnostic-potential-of-the-serological-response-to-synthetic-peptides-from-mycobacterium-tuberculosis-antigens-for-discrimination-between-active-and-latent-tuberculosis-infections/https://catedra-mielomamultiple.com/cd229-ly9-a-novel-biomarker-for-b-cell-malignancies-and-multiple-myeloma/https://catedra-mielomamultiple.com/real-world-data-on-survival-improvement-in-patients-with-multiple-myeloma-treated-at-a-single-institution-over-a-45-year-period/https://catedra-mielomamultiple.com/factors-associated-with-the-clinical-outcome-of-patients-with-relapsed-refractory-cd19-acute-lymphoblastic-leukemia-treated-with-ari-0001-cart19-cell-therapy/https://catedra-mielomamultiple.com/first-report-of-cart-treatment-in-al-amyloidosis-and-relapsed-refractory-multiple-mieloma/https://catedra-mielomamultiple.com/immunoparesis-defined-by-heavy-light-chain-pair-suppression-in-smoldering-multiple-myeloma-shows-initial-isotype-specificity-and-involves-other-isotypes-in-advanced-disease/https://catedra-mielomamultiple.com/predictors-of-return-to-work-after-autologous-stem-cell-transplantation-in-patients-with-multiple-mieloma/https://catedra-mielomamultiple.com/gene-expression-analysis-of-the-bone-marrow-microenvironment-reveals-distinct-immunotypes-in-smoldering-multiple-myeloma-associated-to-progression-to-symptomatic-disease/https://catedra-mielomamultiple.com/kidney-transplantation-in-monoclonal-immunoglobulin-deposition-disease-a-report-of-6-cases/https://catedra-mielomamultiple.com/treatment-of-patients-with-monoclonal-gammopathy-of-clinical-significance/https://catedra-mielomamultiple.com/esat-6-and-ag85a-synthetic-peptides-as-candidates-for-an-immunodiagnostic-test-in-children-with-a-clinical-suspicion-of-tuberculosis/https://catedra-mielomamultiple.com/il-15-enhances-the-persistence-and-function-of-bcma-targeting-car-t-cells-compared-to-il-2-or-il-15-il-7-by-limiting-car-t-cell-dysfunction-and-differentiation/https://catedra-mielomamultiple.com/defining-an-ultra-low-risk-group-in-asymptomatic-igm-monoclonal-gammopathy/https://catedra-mielomamultiple.com/baseline-correlations-and-prognostic-impact-of-serum-monoclonal-proteins-in-follicular-lymphoma/https://catedra-mielomamultiple.com/complement-as-the-enabler-of-carfilzomib-induced-thrombotic-microangiopathy/https://catedra-mielomamultiple.com/expert-review-on-soft-tissue-plasmacytomas-in-multiple-myeloma-definition-disease-assessment-and-treatment-considerations/https://catedra-mielomamultiple.com/impact-of-response-to-treatment-in-health-related-quality-of-life-patient-reported-outcomes-in-elderly-patients-with-relapsed-multiple-mieloma/https://catedra-mielomamultiple.com/consenso-del-grupo-latinoamericano-de-estudio-de-mieloma-multiple-mm-gelamm-para-el-manejo-del-mm-en-estado-de-pandemia-sars-cov-2-covid-19/https://catedra-mielomamultiple.com/the-avoidance-of-g-csf-and-the-addition-of-prophylactic-corticosteroids-after-autologous-stem-cell-transplantation-for-multiple-myeloma-patients-appeal-for-the-at-home-setting-to-reduce-readmission-fo/https://catedra-mielomamultiple.com/a-randomized-phase-3-trial-of-zanubrutinib-vs-ibrutinib-in-symptomatic-waldenstrom-macroglobulinemia-the-aspen-study/https://catedra-mielomamultiple.com/international-myeloma-working-group-risk-stratification-model-for-smoldering-multiple-myeloma-smm/https://catedra-mielomamultiple.com/multiple-myeloma-and-sars-cov-2-infection-clinical-characteristics-and-prognostic-factors-of-inpatient-mortality/https://catedra-mielomamultiple.com/improving-security-of-autologous-hematopoietic-stem-cell-transplant-in-patients-with-light-chain-amyloidosis/https://catedra-mielomamultiple.com/pomalidomide-dexamethasone-for-treatment-of-soft-tissue-plasmacytomas-in-patients-with-relapsed-refractory-multiple-mieloma/https://catedra-mielomamultiple.com/gprc5d-is-a-target-for-the-immunotherapy-of-multiple-myeloma-with-rationally-designed-car-t-cells/https://catedra-mielomamultiple.com/bilateral-orbital-plasmacytomas-as-first-sign-of-extramedullary-progression-post-car-t-therapy-case-report-and-literature-review/https://catedra-mielomamultiple.com/gut-microbiota-influence-in-hematological-malignancies-from-genesis-to-cure/https://catedra-mielomamultiple.com/car-t-cells-in-multiple-myeloma-state-of-the-art-and-future-directions/https://catedra-mielomamultiple.com/supportive-care-in-al-amyloidosis/https://catedra-mielomamultiple.com/future-prospects-of-chimeric-antigen-receptor-t-cell-therapy-for-multiple-mieloma/https://catedra-mielomamultiple.com/the-progress-test-of-the-european-hematology-association-a-new-tool-for-continuous-learning/https://catedra-mielomamultiple.com/2021-european-myeloma-network-review-and-consensus-statement-on-smoldering-multiple-myeloma-how-to-distinguish-and-manage-dr-jekyll-and-mr-hyde/https://catedra-mielomamultiple.com/living-donor-kidney-transplantation-is-an-effective-option-of-renal-replacement-therapy-in-patients-with-light-chain-amyloidosis-al/